NRSN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.815

Open

0.780

VWAP

0.77

Vol

165.99K

Mkt Cap

25.15M

Low

0.750

Amount

128.26K

EV/EBITDA(TTM)

--

Total Shares

33.40M

EV

24.48M

EV/OCF(TTM)

--

P/S(TTM)

--

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Show More

Events Timeline

(ET)

2026-02-18

09:10:00

NeuroSense Releases Long-Term Survival Data from ALS Clinical Trial

2026-02-09 (ET)

2026-02-09

09:30:00

NeuroSense Secures Australian Patent for PrimeC

2026-01-29 (ET)

2026-01-29

17:30:00

NeuroSense Files $150M Mixed Securities Shelf

2025-12-22 (ET)

2025-12-22

09:30:00

NeuroSense Completes Safety Analysis of PrimeC in Alzheimer's Phase 2 Study with No Serious Adverse Events

2025-11-24 (ET)

2025-11-24

10:01:21

NeuroSense Announces FDA Approval to Begin Phase 3 Trial of PrimeC for ALS

2025-08-20 (ET)

2025-08-20

09:48:47

NeuroSense reveals that 20% of ALS patients in Phase 2a study continue treatment with PrimeC

2025-01-06 (ET)

2025-01-06

08:06:45

NeuroSense regains Nasdaq compliance

News

PRnewswire

03-18PRnewswire

NeuroSense to Present PrimeC Data at AD/PD 2026 Conference

PRnewswire

03-16PRnewswire

NeuroSense Publishes ALS Clinical Trial Results in JAMA Neurology

Benzinga

Wall Street Analysts Adjust Ratings on Key Stocks

PRnewswire

03-09PRnewswire

NeuroSense Reports New ALS Treatment Data

PRnewswire

02-18PRnewswire

NeuroSense Releases New ALS Treatment Data

PRnewswire

02-09PRnewswire

NeuroSense Secures Australian Patent, Strengthening Global IP for PrimeC

2 Analyst Rating

Wall Street analysts forecast NRSN stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.50

Averages

8.25

High

9.00

Current: 0.000

Low

7.50

Averages

8.25

High

9.00

Roth Capital

Boobalan Pachaiyappan

initiated

$3

AI Analysis

2026-03-10

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$3

AI Analysis

2026-03-10

initiated

Reason

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of NeuroSense with a Buy rating and $3 price target. The firm is positive on PrimeC's ability to reduce disability and improve survival in amyotrophic lateral sclerosis patients. It estimates PrimeC achieving a peak risk-unadjusted worldwide revenue of $1.5B in 2038.

Noble Capital

Robert LeBoyer

initiated

$9

2025-10-14

Reason

Noble Capital

Robert LeBoyer

Price Target

$9

2025-10-14

initiated

Reason

Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense with an Outperform rating and $9 price target. Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer's disease showed "promising data."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRSN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN.O) is -2.54, compared to its 5-year average forward P/E of -2.10. For a more detailed relative valuation and DCF analysis to assess Neurosense Therapeutics Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.10

Current PE

-2.54

Overvalued PE

-1.10

Undervalued PE

-3.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

11.88

Current PS

54.71

Overvalued PS

46.16

Undervalued PS

-22.41

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stocks are recommended to sell short

Intellectia · 35 candidates

Relative Vol: >= 1.50Short Ratio: MoreThan30PctMoving Average Relationship: PriceBelowMA200

Ticker

Name

Market Cap$

MakeMyTrip Ltd

6.22B

Wyndham Hotels & Resorts Inc

6.01B

Wix.Com Ltd

4.37B

Newsmax Inc

995.59M

Falcon's Beyond Global Inc

805.67M

New Fortress Energy Inc

441.06M

Whales Holding NRSN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Neurosense Therapeutics Ltd (NRSN) stock price today?

The current price of NRSN is 0.753 USD — it has decreased -4.56

What is Neurosense Therapeutics Ltd (NRSN)'s business?

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

What is the price predicton of NRSN Stock?

Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is8.25 USD with a low forecast of 7.50 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Neurosense Therapeutics Ltd (NRSN)'s revenue for the last quarter?

Neurosense Therapeutics Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Neurosense Therapeutics Ltd (NRSN)'s earnings per share (EPS) for the last quarter?

Neurosense Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Neurosense Therapeutics Ltd (NRSN). have?

Neurosense Therapeutics Ltd (NRSN) has 15 emplpoyees as of March 24 2026.

What is Neurosense Therapeutics Ltd (NRSN) market cap?

Today NRSN has the market capitalization of 25.15M USD.